IMMUNO-ONCOLOGY

免疫肿瘤学

• 批准号: 7506791
• 负责人: MATTHEW D SCHARFF
• 金额: $ 2.65万
• 依托单位: ALBERT EINSTEIN COLLEGE OF MEDICINE
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-09-25 至 2012-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7506791
• 关键词: Albert Einstein Cancer Center; Antigens; B-Cell Lymphomas; Cancer Center Support Grant; Cancer Vaccines; Cervical; Clinical; Clinical Research; Clinical Trials; Collaborations; Community Clinical Oncology Program; Defect; Development; Evolution; Faculty; Generation of Antibody Diversity; Genomic Instability; Goals; Grant; Immunoglobulin Genes; Immunotherapy; Lead; Link; Lymphoma; Malignant Neoplasms; Melanins; Mutation; Neoplasms; Paper; Pathogenesis; Peptides; Pharmacologic Substance; Physicians; Preparation; Process; Proteins; Radio; Radioisotopes; Rate; Research; Research Personnel; Role; Scientist; Solid Neoplasm; T-Lymphocyte; Therapeutic; Time; United States National Institutes of Health; Vaccines; Variant; Viral; college; immunogenicity; inhibitor/antagonist; large cell Diffuse non-Hodgkin' s lymphoma; member; oncology; prevent; programs; response; therapeutic target; tumor

The Immuno-oncology Program has traditionally represented a major focus of basic scientific strength at AECC and at the last CCSG review was rated as excellent. Since that time this program has greatly increased its cancer focus through changes in membership, the evolution of research of existing members and the recruitment of new faculty, several of whom are physician-scientists, to the College and this Program. These changes were a natural evolution program member's research and a response to the previous summary statement. The goals of the Immuno-oncology program are: 1) To determine how defects in the targeting of the genomic instability of immunoglobulin genes required for the generation of antibody diversity lead to the mutations and translocations that cause B cell lymphomas and to search for ways to prevent such errors. One objective is to develop therapeutics targeted specifically to molecularly distinct Bcell lymphoma variants. 2) To better understand how antigen is presented to T cells and how to manipulate that process to increase the immunogenicity of tumors and cancer vaccines. 3) To develop and apply new immune therapies with a focus on radio-immunotherapy and vaccines to viral-induced tumors. Translational accomplishments include the development of a anti-melanin-mAb-radionuclide therapeutic, which emerged from studies on fungal melanin, that will enter clinical trials in 2007. Studies focused on the role of Bcl6 in the pathogenesis of diffuse large B cell lymphoma have identified a peptide inhibitor of the interaction between this protein and its corepressor. This peptide is active pre-clinically, and is being further developed in preparation for transition to a pharmaceutical company for clinical studies. The recruitment of two secondary members to this program has linked clinical and basic investigators who study vaccines within the context of clinical trials focused on the treatment of cervical neoplasia and other solid tumors. There are currently 16 program members from 11 departments, of whom 11 are primary members, supported by 6 NCI ($1.45M Direct) and 7 other NIH grants. Since the last CCSG review there have been 176 cancer-relevant research papers by members of this program of which 7% represent intraprogrammatic, and 19% represent interprogrammatic collaborations.

免疫肿瘤学项目传统上代表了基础科学实力的主要焦点 AECC 和上次 CCSG 评审中均被评为优秀。从那时起，这个程序就极大地 通过成员的变化、现有成员研究的发展，增加了对癌症的关注 以及为学院招募新教职人员，其中几位是医师科学家 程序。这些变化是自然进化计划成员的研究以及对 之前的摘要声明。免疫肿瘤学计划的目标是： 1) 确定缺陷如何 靶向产生抗体所需的免疫球蛋白基因的基因组不稳定性 多样性导致突变和易位，从而导致 B 细胞淋巴瘤，并寻找方法 防止此类错误。一个目标是开发专门针对分子独特的 B 细胞的疗法 淋巴瘤变种。 2) 更好地了解抗原如何呈递给T细胞以及如何操纵 该过程可以增加肿瘤和癌症疫苗的免疫原性。 3）开发和应用新的 免疫疗法，重点是放射免疫疗法和病毒诱发肿瘤的疫苗。翻译性 成就包括开发了一种抗黑色素单克隆抗体放射性核素治疗剂，该疗法的出现 来自真菌黑色素研究，该研究将于 2007 年进入临床试验。研究重点是 Bcl6 在 弥漫性大 B 细胞淋巴瘤的发病机制已鉴定出一种肽抑制剂 这种蛋白质及其辅阻遏物。该肽在临床前具有活性，并且正在进一步开发 为过渡到制药公司进行临床研究做准备。招聘两名中专 该计划的成员将在以下背景下研究疫苗的临床和基础研究人员联系起来 临床试验重点关注宫颈肿瘤和其他实体瘤的治疗。目前有16个 来自 11 个部门的计划成员，其中 11 名是主要成员，由 6 个 NCI 提供支持（145 万美元） 直接）和 7 项其他 NIH 拨款。自上次 CCSG 审查以来，已有 176 项癌症相关研究 该计划成员的论文，其中 7% 代表计划内，19% 代表 计划间合作。